| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 129.16M | 26.68M | 335.66M | 48.66M | 108.46M | 330.53M | 0 |
| Revenue Growth % | - | - | - | - | -0.79% | 11.58% | -0.86% | 1.23% | 2.05% | -1% |
| Cost of Goods Sold | 121K | 1.47M | 3.08M | 7.42M | 193.38M | 212.62M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | 0.06% | 7.25% | 0.63% | - | - | - | - |
| Gross Profit | -121K | -1.47M | -3.08M | 121.75M | -166.7M | 123.04M | 48.66M | 108.46M | 330.53M | 0 |
| Gross Margin % | - | - | - | 0.94% | -6.25% | 0.37% | 1% | 1% | 1% | - |
| Gross Profit Growth % | - | -11.14% | -1.1% | 40.5% | -2.37% | 1.74% | -0.6% | 1.23% | 2.05% | -1% |
| Operating Expenses | 16.68M | 87.43M | 90.14M | 175.53M | 46.48M | 60.33M | 344.41M | 449.21M | 527.23M | 487.34M |
| OpEx % of Revenue | - | - | - | 1.36% | 1.74% | 0.18% | 7.08% | 4.14% | 1.6% | - |
| Selling, General & Admin | 5.11M | 11.73M | 15.68M | 32.35M | 46.48M | 60.33M | 79.06M | 90.47M | 103.35M | 105.44M |
| SG&A % of Revenue | - | - | - | 0.25% | 1.74% | 0.18% | 1.62% | 0.83% | 0.31% | - |
| Research & Development | 11.57M | 75.7M | 74.46M | 143.18M | 193.38M | 212.62M | 265.35M | 358.73M | 423.88M | 396.44M |
| R&D % of Revenue | - | - | - | 1.11% | 7.25% | 0.63% | 5.45% | 3.31% | 1.28% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -193.38M | -212.62M | 0 | 0 | 0 | -14.54M |
| Operating Income | -16.68M | -87.43M | -90.14M | -46.37M | -213.18M | 62.72M | -295.75M | -340.74M | -196.7M | -487.34M |
| Operating Margin % | - | - | - | -0.36% | -7.99% | 0.19% | -6.08% | -3.14% | -0.6% | - |
| Operating Income Growth % | - | -4.24% | -0.03% | 0.49% | -3.6% | 1.29% | -5.72% | -0.15% | 0.42% | -1.48% |
| EBITDA | -16.56M | -85.96M | -87.06M | -38.96M | -205.19M | 71.25M | -287.16M | -330.36M | -179.97M | -478.35M |
| EBITDA Margin % | - | - | - | -0.3% | -7.69% | 0.21% | -5.9% | -3.05% | -0.54% | - |
| EBITDA Growth % | - | -4.19% | -0.01% | 0.55% | -4.27% | 1.35% | -5.03% | -0.15% | 0.46% | -1.66% |
| D&A (Non-Cash Add-back) | 121K | 1.47M | 3.08M | 7.42M | 7.99M | 8.53M | 8.59M | 10.38M | 16.73M | 8.99M |
| EBIT | -16.68M | -87.43M | -90.14M | -46.37M | -213.18M | 62.72M | -295.75M | -340.74M | -196.7M | -501.88M |
| Net Interest Income | -109K | 0 | 0 | 10.13M | 15.22M | 9.24M | 4.59M | 14.77M | 51.51M | 64.64M |
| Interest Income | 0 | 781K | 1.96M | 10.13M | 15.22M | 9.24M | 4.59M | 14.77M | 51.51M | 64.64M |
| Interest Expense | 109K | 0 | 1.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -109K | 781K | 1.96M | 10.13M | 15.92M | 9.24M | 4.59M | 14.77M | 51.51M | 64.64M |
| Pretax Income | -16.79M | -86.65M | -88.19M | -36.24M | -197.26M | 71.96M | -291.16M | -325.97M | -145.19M | -422.7M |
| Pretax Margin % | - | - | - | -0.28% | -7.39% | 0.21% | -5.98% | -3.01% | -0.44% | - |
| Income Tax | 0 | 0 | 0 | 0 | 351K | 823K | -575K | 21K | 30K | 68K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.99% | 1% | 1% | 1% | 1% |
| Net Income | -16.79M | -86.65M | -88.19M | -36.24M | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M | -422.77M |
| Net Margin % | - | - | - | -0.28% | -7.41% | 0.21% | -5.97% | -3.01% | -0.44% | - |
| Net Income Growth % | - | -4.16% | -0.02% | 0.59% | -4.45% | 1.36% | -5.08% | -0.12% | 0.55% | -1.91% |
| Net Income (Continuing) | -16.79M | -86.65M | -88.19M | -36.24M | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M | -422.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.58 | -13.49 | -5.89 | -0.39 | -2.07 | 0.63 | -2.39 | -2.60 | -1.06 | -2.57 |
| EPS Growth % | - | -1.42% | 0.56% | 0.93% | -4.31% | 1.3% | -4.79% | -0.09% | 0.59% | -1.42% |
| EPS (Basic) | -5.58 | -13.49 | -5.89 | -0.39 | -2.07 | 0.65 | -2.39 | -2.60 | -1.06 | -2.57 |
| Diluted Shares Outstanding | 3.01M | 6.42M | 14.96M | 92.62M | 95.61M | 112.7M | 121.52M | 125.53M | 137.37M | 164.47M |
| Basic Shares Outstanding | 3.01M | 6.42M | 14.96M | 92.62M | 95.61M | 108.97M | 121.52M | 125.53M | 137.37M | 164.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 33.43M | 181.96M | 409.61M | 480.84M | 430.03M | 1.5B | 897.23M | 1.37B | 1.06B | 864.44M |
| Cash & Short-Term Investments | 30.74M | 178.33M | 406.23M | 464.3M | 415.36M | 1.47B | 865.41M | 1.34B | 1.03B | 832.33M |
| Cash Only | 30.74M | 39.85M | 218.38M | 77.12M | 79.45M | 507.14M | 293.48M | 218.04M | 127.11M | 174.96M |
| Short-Term Investments | 0 | 138.48M | 187.85M | 387.17M | 335.91M | 962.55M | 571.93M | 1.12B | 907.4M | 657.37M |
| Accounts Receivable | 0 | 438K | 464K | 8.55M | 0 | 0 | 1.23M | 9.28M | 3.42M | 2.17M |
| Days Sales Outstanding | - | - | - | 24.15 | - | - | 9.2 | 31.24 | 3.78 | - |
| Inventory | 0 | 0 | -464K | -8.55M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 1.35M | 0 | 25.96M | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 3.25M | 89.11M | 77.11M | 181.15M | 123.2M | 108.63M | 506.93M | 87.92M | 89.78M | 509.74M |
| Property, Plant & Equipment | 3.17M | 15.26M | 14.92M | 25.16M | 80.66M | 73.46M | 69.61M | 74.52M | 71.64M | 125.63M |
| Fixed Asset Turnover | - | - | - | 5.13x | 0.33x | 4.57x | 0.70x | 1.46x | 4.61x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 84K | 73.08M | 60.75M | 147.88M | 39.89M | 34.2M | 425.45M | 0 | 0 | 359.37M |
| Other Non-Current Assets | 0 | 770K | 1.44M | 8.11M | 2.66M | 962K | 11.87M | 13.4M | 18.14M | 24.74M |
| Total Assets | 36.68M | 271.07M | 486.72M | 661.98M | 553.23M | 1.6B | 1.4B | 1.46B | 1.15B | 1.37B |
| Asset Turnover | - | - | - | 0.20x | 0.05x | 0.21x | 0.03x | 0.07x | 0.29x | - |
| Asset Growth % | - | 6.39% | 0.8% | 0.36% | -0.16% | 1.9% | -0.12% | 0.04% | -0.21% | 0.19% |
| Total Current Liabilities | 3.48M | 9.11M | 14.16M | 32.79M | 45.34M | 71.7M | 378.25M | 363.92M | 77.98M | 102.21M |
| Accounts Payable | 1.71M | 1.96M | 2.72M | 1.89M | 2.59M | 1.07M | 4.78M | 2.79M | 9.48M | 11.14M |
| Days Payables Outstanding | 5.17K | 487.74 | 321.65 | 93.08 | 4.89 | 1.84 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 4.69M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 148K | 701K | 918K | 9.52M | 8.74M | 21.95M | 19.01M | 17.09M | 21.59M | 38.86M |
| Current Ratio | 9.60x | 19.98x | 28.92x | 14.67x | 9.48x | 20.86x | 2.37x | 3.77x | 13.65x | 8.46x |
| Quick Ratio | 9.60x | 19.98x | 28.95x | 14.93x | 9.48x | 20.86x | 2.37x | 3.77x | 13.65x | 8.46x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 48.84M | 7.44M | 6.76M | 82.35M | 113M | 382.05M | 63.63M | 53.89M | 44.98M | 42.29M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 68.86M | 64.17M | 58.55M | 53.03M | 44.98M | 36.67M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 48.84M | 7.44M | 6.76M | 25M | 379K | 701K | 379K | 379K | 0 | 5.62M |
| Total Liabilities | 52.32M | 16.55M | 20.93M | 115.14M | 158.34M | 453.75M | 441.87M | 417.81M | 122.96M | 144.5M |
| Total Debt | 0 | 0 | 0 | 0 | 72.53M | 68.86M | 64.01M | 60.35M | 52.24M | 48.71M |
| Net Debt | -30.74M | -39.85M | -218.38M | -77.12M | -6.92M | -438.28M | -229.47M | -157.69M | -74.86M | -126.25M |
| Debt / Equity | - | - | - | - | 0.18x | 0.06x | 0.07x | 0.06x | 0.05x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | 0.97x | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | -6.15x | - | - | - | - |
| Interest Coverage | -153.02x | - | -46.11x | - | - | - | - | - | - | - |
| Total Equity | -15.63M | 254.52M | 465.8M | 546.85M | 394.89M | 1.15B | 962.29M | 1.04B | 1.03B | 1.23B |
| Equity Growth % | - | 17.28% | 0.83% | 0.17% | -0.28% | 1.91% | -0.16% | 0.08% | -0.01% | 0.19% |
| Book Value per Share | -5.20 | 39.62 | 31.13 | 5.90 | 4.13 | 10.21 | 7.92 | 8.30 | 7.50 | 7.48 |
| Total Shareholders' Equity | -15.63M | 254.52M | 465.8M | 546.85M | 394.89M | 1.15B | 962.29M | 1.04B | 1.03B | 1.23B |
| Common Stock | 170K | 2.69M | 1.2M | 1.27M | 1.29M | 1.53M | 1.55M | 1.69M | 1.71M | 1.77M |
| Retained Earnings | -16.86M | -103.51M | -191.7M | -227.94M | -425.55M | -354.42M | -645M | -970.99M | -1.12B | -1.54B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -48.31M | -373K | -368K | -649K | 350K | -245K | -2.5M | -6.89M | 643K | 2.02M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.05M | -72.36M | -76.64M | 50.12M | -151.58M | 416.15M | -211.39M | -244.72M | -357.99M | -347.69M |
| Operating CF Margin % | - | - | - | 0.39% | -5.68% | 1.24% | -4.34% | -2.26% | -1.08% | - |
| Operating CF Growth % | - | -3.81% | -0.06% | 1.65% | -4.02% | 3.75% | -1.51% | -0.16% | -0.46% | 0.03% |
| Net Income | -16.79M | -86.65M | -88.19M | -36.24M | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M | -422.77M |
| Depreciation & Amortization | 121K | 1.47M | 3.08M | 7.42M | 7.99M | 8.53M | 8.59M | 10.38M | 16.73M | 8.99M |
| Stock-Based Compensation | 479K | 2.95M | 4.41M | 18.79M | 38.38M | 50.35M | 85.25M | 99.85M | 0 | 102.88M |
| Deferred Taxes | 0 | 307K | 0 | 0 | 0 | 55K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 710K | 5.28M | 754K | -2.74M | -3.25M | -2.32M | 5.76M | -4.92M | 60.43M | -53.73M |
| Working Capital Changes | 426K | 4.29M | 3.31M | 62.89M | 2.92M | 288.4M | -20.41M | -24.03M | -289.93M | 16.94M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.68M | 161K | 207K | -526K | 1.03M | -1.62M | 3.71M | 2.27M | 2.43M | 1.44M |
| Cash from Investing | -3.06M | -219M | -41.17M | -287.42M | 147.71M | -623.21M | -21.63M | -141.39M | 249.31M | -88.76M |
| Capital Expenditures | -3.06M | -6.13M | -2.88M | -3.39M | -17.92M | -3.1M | -8.5M | -17.83M | -12.94M | -15.91M |
| CapEx % of Revenue | - | - | - | 0.03% | 0.67% | 0.01% | 0.17% | 0.16% | 0.04% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -212.87M | -38.29M | -284.03M | 0 | -620.11M | 0 | -123.55M | 0 | 0 |
| Cash from Financing | 48.85M | 300.48M | 296.32M | 97.02M | 6.19M | 634.75M | 19.35M | 310.67M | 17.82M | 484.3M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 510K | 111K | 733K | 2.61M | 6.19M | 20.66M | 19.35M | 14.46M | 0 | 17.39M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.11M | -78.49M | -79.51M | 46.72M | -169.5M | 413.06M | -219.89M | -262.55M | -370.93M | -363.61M |
| FCF Margin % | - | - | - | 0.36% | -6.35% | 1.23% | -4.52% | -2.42% | -1.12% | - |
| FCF Growth % | - | -3.33% | -0.01% | 1.59% | -4.63% | 3.44% | -1.53% | -0.19% | -0.41% | 0.02% |
| FCF per Share | -6.03 | -12.22 | -5.31 | 0.50 | -1.77 | 3.67 | -1.81 | -2.09 | -2.70 | -2.21 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.84x | 0.87x | -1.38x | 0.77x | 5.85x | 0.73x | 0.75x | 2.47x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 210K | 47K | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -72.55% | -24.49% | -7.16% | -41.97% | 9.21% | -27.51% | -32.52% | -14.01% | -37.4% |
| Return on Invested Capital (ROIC) | - | -77.93% | -29.26% | -9.7% | -37.28% | 8.55% | -30.7% | -31.6% | -16.03% | -35.49% |
| Gross Margin | - | - | - | 94.26% | -624.87% | 36.66% | 100% | 100% | 100% | - |
| Net Margin | - | - | - | -28.06% | -740.74% | 21.19% | -597.15% | -300.56% | -43.94% | - |
| Debt / Equity | - | - | - | - | 0.18x | 0.06x | 0.07x | 0.06x | 0.05x | 0.04x |
| Interest Coverage | -153.02x | - | -46.11x | - | - | - | - | - | - | - |
| FCF Conversion | 0.90x | 0.84x | 0.87x | -1.38x | 0.77x | 5.85x | 0.73x | 0.75x | 2.47x | 0.82x |
| Revenue Growth | - | - | - | - | -79.34% | 1158.19% | -85.5% | 122.9% | 204.74% | -100% |
| 2018 | 2019 | 2020 | |
|---|---|---|---|
| Alzheimer's Disease Services | 3.9M | 3.5M | 3.4M |
| Alzheimer's Disease Services Growth | - | -10.26% | -2.86% |
Denali Therapeutics Inc. (DNLI) saw revenue decline by 100.0% over the past year.
Denali Therapeutics Inc. (DNLI) reported a net loss of $498.7M for fiscal year 2024.
Denali Therapeutics Inc. (DNLI) has a return on equity (ROE) of -37.4%. Negative ROE indicates the company is unprofitable.
Denali Therapeutics Inc. (DNLI) had negative free cash flow of $410.8M in fiscal year 2024, likely due to heavy capital investments.